TY -的A2 Brunetti安东尼奥盟——Yabiku Koichi盟——Nakamoto Keiko盟——Tsubakimoto Maho PY - 2020 DA - 2020/12/29 TI - Sodium-Glucose转运蛋白2抑制葡萄糖代谢的影响,肝功能、腹水、血液动力学的非酒精性脂肪肝炎小鼠模型和2型糖尿病SP - 1682904六世- 2020 AB -许多血液降糖药物不能一次使用2型糖尿病患者(T2D)和非酒精性脂肪肝病发展非酒精性脂肪肝(NASH)。因此,这类病人往往需要胰岛素治疗。我们旨在确定sodium-glucose转运蛋白2抑制剂的影响(SGLT2i) dapagliflozin单一疗法在葡萄糖代谢纳什/ T2D的小鼠模型,关注其利尿效果。模仿腹水和成像来确定其严重性,葡甲胺钠amidotrizoate (MSA)注入到小鼠的腹腔内。减少引起的腹水dapagliflozin相比,使用microcomputed断层呋喃苯胺酸引起的。每种药物对血液动力学的影响也比较。dapagliflozin-related改善葡萄糖耐量实现在高脂肪饮食的老鼠(HFD)或一个HFD + methionine-and-choline-deficient饮食(MCDD)。dapagliflozin-treated纳什老鼠,低血糖并不确定在24小时随意的血糖监测。在dapagliflozin furosemide-treated组,人工腹水的决议所花费的时间明显短于对照组,以及这些组之间没有明显差异。呋喃苯胺酸显著降低血压和心率显著增加的老鼠。 Dapagliflozin caused a mild decrease in systolic, but not diastolic blood pressure, and the heart rate and circulating catecholamine and renin-aldosterone concentrations were unaffected. Dapagliflozin treatment improved glycemic control in the NASH mice versus untreated mice. Thus, dapagliflozin had a prompt diuretic effect but did not adversely affect the hemodynamics of mice with NASH and T2D. Therefore, it may be useful for the treatment of patients with both T2D and liver cirrhosis. SN - 2314-6745 UR - https://doi.org/10.1155/2020/1682904 DO - 10.1155/2020/1682904 JF - Journal of Diabetes Research PB - Hindawi KW - ER -